Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h

News May 24, 2010

Executives from Heptares Therapeutics and Oxygen Healthcare (O2h) announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”

Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”

Taming Turbulence

News

For scientists wrestling with problems as diverse as containing superhot plasma in a fusion reactor, improving the accuracy of weather forecasts, or probing the unexplained dynamics of a distant galaxy, turbulence-spawning shear flow is a serious complicating factor. A new supercomputer-powered effort aims to make modelling shear far easier.

Microfluidic Test Detects Those Ovulating, Based on Saliva Patterns

News

Advancements in microfluidics, artificial intelligence (AI) and the ubiquity of smartphones have lead to an ovulation testing tool that can automatically detect fern patterns - a marker of ovulation - in a saliva sample.

50% of Trial Subjects Who Took a Placebo Reported Suffering an Adverse Event

News

Research published today in Trials explores the negative effects that can be caused by participants being administered placebos in clinical trials, finding that half of people taking placebos reported side effects from the trial intervention.

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free